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Introduction
As components of the innate immune response, dendritic cells 
(DCs) are involved in the initial reactions to infection, as they 
detect foreign antigens and are activated by stimuli, such as 
pathogen-associated molecular patterns (PAMPs), unique to 
invading pathogens.1-3 PAMPs, including lipopolysacharides and 
cytosine-guanosine (CpG) sequences in bacterial DNA, trigger 
a particular toll-like receptor (TLR) that allows DCs to clas-
sify the pathogen and induce their expression of T cell-activat-
ing molecules.4 Activated DCs then migrate to draining lymph 
nodes (LNs), where they prime the appropriate T-cell response 
via the presentation of antigen, costimulatory molecules and the 
appropriate cytokines.1 While innate immunity encompasses 
many rapid reactions to infection, adaptive immunity, in con-
trast, is learned or acquired more slowly via cellular messengers 
(for example, DCs) over time frames of days to weeks.5-9 For 
example, transplantation of infected tissue into mice results in 
DC infiltration and innate activation, within 3 d, followed by 
peak T-cell expansion after 9 d.10
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Current vaccine methods produce short-lived bioactivity, and 
cancer vaccines have failed to reproducibly cause the regression 
of solid tumors.11,12 Current delivery methods for experimental 
vaccines often include bolus injections/effusions of antigen and 
adjuvants with short half-lives or activated cell products that lose 
significant viability upon in vivo transplantation.1-3,13 Biomaterials 
may be utilized to extend the duration of immunostimulation 
and have been studied extensively in vaccine formulations as 
adjuvants and to enable controlled presentation of antigens to 
the immune system.14,15 More recently, material-based particulate 
systems have been developed to control antigen localization in 
tissue or to target host DCs specifically via antibody or ligand 
conjugation.14,16,17 Although current biomaterial-based vaccines 
can enhance antigen loading to DCs, leading to antigen-specific 
T-cell activation, they lack concurrent regulation of effector T-cell 
activity. Therapeutic vaccination against an established disease, 
including solid tumors, requires methods that stimulate not only 
innate immunity and DCs, but also persistent cytotoxic T lym-
phocyte (CTL) responses, which kill tumor cells until the disease 
has cleared. Therefore, the natural kinetics of innate and adaptive 
cancer vaccines are typically formulated for bolus injection and often produce short-lived immunostimulation resulting in 
poor temporal control over immune cell activation and weak oncolytic activity. One means of overcoming these limitations 
utilizes immunologically active biomaterial constructs. We previously reported that antigen-laden, macroporous pLG 
scaffolds induce potent dendritic cell (Dc) and cytotoxic T-lymphocyte (cTL) responses via the controlled signaling of 
inflammatory cytokines, antigen and toll-like receptor agonists. In this study, we describe the kinetics of these responses 
and illustrate their fundamental relationship to potent tumor rejection when implanted subcutaneously in a mouse B16 
model of melanoma. By explanting scaffolds from mice at times ranging from 1–7 d, a seamless relationship was observed 
between the production of controlled cTL responses, tumor growth and long-term survival in both prophylactic and 
therapeutic models. Scaffolds must be implanted for > 7 d to augment cTL responses via the prolonged presentation of 
tumor antigen, and the benefits included a notable regression of established tumors. host Dc infiltration into the porous 
material persisted for 12 days (peaking at day 5 ~1.4 x 106 cells), and a sharp attenuation in Dc numbers coincided with 
peak cD8+ cTL infiltration at day 12 (~8 x 105 cells). Importantly, these pLG systems enhanced Dc numbers in the draining 
lymph node, resulting in increased cD8(+) cTL subsets at days 10–16 of vaccination. These results indicate that material 
systems can finely control innate and adaptive immune cell responses to kill typically untreatable melanoma tumors and 
provide critical kinetic data for the design of vaccine carriers.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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immune responses and the coordination of these responses by 
vaccine vectors should impact vaccine design and application.
We recently described the development of three-dimensional, 
macroporous poly(lactide-co-glycolide; PLG) matrices that 
regulate the trafficking and activation of dendritic cells (DCs) 
in situ.5,6 These implantable matrices spatially and temporally 
control the in vivo presentation of cytokines, tumor antigens 
and danger signals.18,19 Fabricated with GM-CSF, a CpG oligo-
nucleotide (ODN) and tumor lysate, these PLG vaccines release 
GM-CSF into the surrounding tissue, forming GM-CSF gradi-
ents that recruit host DCs18-21 following subcutaneous implanta-
tion. CpG-rich ODNs, which act as danger signals, and antigen 
(tumor lysate incorporated within the PLG) are embedded in 
the matrix or slowly released to matrix resident DCs, which pro-
gram DC development and maturation. The coordination of DC 
activation induced by these biomaterial-based vaccines promotes 
potent, prolonged and specific cytotoxic T cell-mediated immu-
nity that has been shown to eradicate large established peripheral 
tumors in mice.18,19 In side-by-side comparisons, this vaccine sys-
tem outperformed clinically tested cell-based vaccines and for-
mulations of equivalent doses delivered in bolus, demonstrating 
the importance of the material backbone.19 Importantly, in con-
trolled experiments of vaccine efficacy, it was demonstrated that 
the presentation of all three bioactive components (GM-CSF, 
CpG-ODN and tumor lysate) of the vaccine system were required 
to induce immune-mediated destruction of tumors.18,19
In this report, we study the relationship between vaccine dura-
tion and efficacy in melanoma models and its correlation to local 
kinetics of DC and T-cell responses to the aforementioned PLG 
vaccine system. The duration of vaccination was varied to deter-
mine the impact on vaccine efficacy. The report also describes 
the kinetics of innate (DCs) and adaptive cellular responses 
(cytotoxic T cells) to these vaccines and highlights the inflection 
point, when innate responses transition to effective anti-tumor 
immune responses after vaccination. Because the cytokines inter-
leukin (IL)-12 and interferon (IFN)γ are important mediators 
and indicators of T helper (Th)-1 and cytotoxic T-cell responses 
to viruses and tumors,5,22,23 we also measured their concentra-
tions at the PLG vaccine site over time. Additionally, the vac-
cine’s induction of systemic cellular responses as monitored at the 
inguinal LN draining the site of vaccination, as these are points 
where naïve T cells interact with antigen-presenting cells (APCs; 
DCs and macrophages) and are important locations where CD8+ 
CTL cells are primed.9
Results
The cross-section of the macroporous PLG vaccine is shown in 
an SEM micrograph in Figure 1A. As previously reported, the 
matrices were largely porous, isoreticulated scaffolds with an 
overall porosity of approximately 85%. The melanoma vaccines 
contained 680 ± 26 μg of protein (n = 4) derived from melanoma 
tumor lysate, 2.5 ± 0.3 μg of GM-CSF (n = 8) and 150 ± 2.0 μg 
of CpG-ODN (n = 8).
Effect of vaccine duration on vaccine efficacy. As described 
previously, macroporous PLG scaffolds were fabricated to control 
the presentation of GM-CSF, tumor lysate (B16 melanoma) and 
CpG-ODN18,19 to serve as vaccines (PLG vaccines) (Fig. 1A 
and B). The duration of vaccination was controlled by explanting 
the material system at various time points, and we tested the rela-
tionship between vaccine duration and efficacy in prophylactic 
and therapeutic B16-F10 melanoma models. PLG vaccines were 
implanted subcutaneously into the backs of C57BL/6J mice and 
removed at days 1, 3, 7, 12 and 16 after implantation, and these 
mice were challenged at day 14 with an otherwise lethal dose of 
B16-F10 cells (Fig. 1C). Prophylactic vaccination times of less 
than 7 d resulted in little survival benefit (Fig. 1D). However, 
vaccination times of 7, 12 and 16 d resulted in significant long-
term survival, as 60 and 80 percent of animals survived tumor 
challenge (Fig. 1D and E). Continuous vaccination (matrix 
not removed) conferred a small increase in immune protection 
(90% survival) over vaccination times of 16 d (80% survival). 
These results clearly indicate that longer-term antigen/immune 
cell stimulation was required to induce significant protection.
The relationship between vaccine duration and tumor rejec-
tion was also determined by varying vaccination times in ther-
apeutic treatment of established B16 melanomas. Mice were 
inoculated with 105 B16 tumor cells, and melanomas were 
allowed to develop for 9 d, at which point animals received PLG 
vaccines. Vaccination was then arrested by the removal of the 
implant at days 1, 3, 7, 12 and 16 after implantation (Fig. 1C). 
Therapeutic vaccination times of less than 7 d had no impact on 
tumor progression (Fig. 1F). Vaccination times of greater than 
12 d significantly impacted tumor progression and extended 
the lifespan of mice (Fig. 1F). Importantly, continuous vaccina-
tion (> 16 d) prolonged anti-tumor attack and the suppression 
of tumor growth and conferred a three-fold increase in median 
survival (Fig. 1F).
Kinetics of DC and T-cell responses at PLG vaccine site. 
To further delineate the relation between the duration of vac-
cination and the associated immunologic response, the kinet-
ics of cell recruitment by the PLG vaccines was quantified. The 
engineered PLG matrices were designed to release a pulse of 
GM-CSF to recruit host DCs.18,20,21 Histological analysis at day 
14 post-implantation of PLG matrices loaded with 3,000 ng of 
GM-CSF revealed enhanced cellular infiltration and penetration 
into the void volume of the material relative to cell infiltration at 
3 d after implantation (Fig. 2A). As described previously, these 
PLG vaccines are embedded with B16 melanoma tumor lysates 
and CpG-ODN molecules to serve as tumor antigen and danger 
signals to infiltrating immune cells.18 Incorporation of approxi-
mately 680 μg of protein derived from B16-F10 melanoma tumor 
lysate resulted in sustained release of tumor-associated proteins 
for at least 40 d in vitro, with approximately 80 μg being released 
between days 5 and 40 (Fig. S1). At day 40 the percent of tumor 
protein retained within the matrix remained high (77%), indi-
cating that the vaccine serves as a site of sustained antigen pre-
sentation that may program immune cells for extended periods.
To assess the kinetics of DC and T-cell responses to PLG vac-
cines, matrices were explanted at various times, and total cell 
infiltrates were isolated and analyzed using FACS analysis to 
determine CD11c(+) DC and the CD3(+) T-cell subpopulations. ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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Figure 1A–E. effect of pLG vaccine duration on efficacy in B16 melanoma tumor models. (A) photomicrograph of surface of macroporous, pLG-based 
vaccine loaded with GM-cSF, tumor lysates and cpG-ODN. (B) SeM micrograph of cross-section of macroporous, pLG vaccine. Scale bar-200 μm. (c) 
Schematic of pLG vaccine regimen for both prophylactic and therapeutic B16 models in mice. (prophylactic) vaccine duration is varied from 0, 1, 3, 7, 
12 and 16 d. (D) A comparison of the survival time and (e) the survival percentage at day 100 of mice treated with blank pLG scaffolds and pLG vaccines 
for a duration of 1, 3, 7, 12, 16 d or indefinitely (> 16). Mice were challenged with 105 B16-F10 melanoma tumor cells at day 14 after the start of vaccina-
tion.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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Figure 1F. effect of pLG vaccine duration on efficacy in B16 melanoma 
tumor models. (F) effect of vaccine duration on therapeutic efficacy 
(therapeutic). Tumor growth curves for mice vaccinated at day 9 after 
tumor challenge (105 B16 melanoma cells), with pLG vaccines for a dura-
tion of 1, 3, 7, 12, 16 d or indefinitely (> 16). The total GM-cSF dose was 
approximately 3,000 ng, and cpG-ODN dose was approximately 100 μg. 
Values in (F) represent mean and standard error.
DC numbers were detectable at day 3 post-implantation, peaked 
at days 5 and 7 (Fig. 2B and C) and dropped sharply at day 12 
post-implantation. The T-cell response to PLG vaccines is pre-
dominantly comprised of CD8(+) cytotoxic T cells (Fig. 2D). 
Local cytotoxic T-cell responses persisted at significant levels 
between days 7 and 28 after implantation. These data indicate 
that the vaccine site transitions from primarily activating innate 
immune responses and DCs to a T-cell effector site between 7 
to 12 d after implantation, and this CD8(+) T-cell response is 
maintained for at least 28 d.
Kinetics of IL-12 and IFNγ production at vaccine site. 
IL-12, which is a T-cell growth and stimulating factor and an 
activating factor for DCs, is produced by DCs and macrophages 
in response to intercellular pathogens and tumor cells. Local 
IL-12 concentrations peaked at 800 ρg/ml after one day of vac-
cination and then subsided to approximately 300 ρg/ml between 
days 5–16 of vaccination (Fig. 3A). Peak levels of IL-12 corre-
lated with the infiltration of CD14(+) monocytes and CD11b(+) 
macrophages, and these cells were likely the primary producers 
of IL-12 from days 1–3 after vaccination (Fig. 3A and Fig. S2). 
All three components of the vaccine, GM-CSF, CpG-ODN and 
tumor lysates were required to promote and maintain high IL-12 
concentrations as blank controls, and all other combinations of 
the vaccine’s bioactive factors produced significantly lower IL-12 
levels (Fig. 3B). Interestingly, the IL-12 concentration subsided 
to undetectable levels after day 21 of vaccination, and the time 
over which IL-12 was detected coincided with the time course of 
macrophage, monocyte and DC infiltration (Fig. 2B and C and 
Fig. S2) at the vaccine site. IFNγ levels at the vaccine sites were 
first detected at day 3 after vaccination, peaked at day 12 and 
subsided at days 16–21; these kinetics mirror the time-course 
of T-cell infiltration (Figs. 2B, 2C and 3C). Altogether, this 
data indicates that DCs are exposed to high IL-12 concentra-
tions while the CpG-ODN danger signals and tumor lysates are 
presented from the vaccine. Provision of CpG-ODN signaling 
into the vaccine dramatically increased IFNγ production in situ 
(Fig. 3D), likely due to their role in promoting DC activation 
(including ligation of TLR-9),24 and this cytokine is also hallmark 
of cytotoxic T-cell activity and Th1 responses.22-24 Importantly, 
PLG vaccines sustained the induction of IL-12 and IFNγ from 
infiltrating immune cells for 16 d, demonstrating Th1 polariza-
tion in the immune response and suggesting prolonged CD8(+) 
CTL activity5,19,22,23 to the tumor antigens embedded within the 
vaccine’s matrix.18,19
Effects of PLG vaccination on cell populations in draining 
LN. To determine the systemic effects of PLG vaccines, cellu-
lar populations in the draining LNs were monitored over time. 
Blank matrices and PLG matrices containing GM-CSF, lysate 
and CpG-ODN (PLG vaccines) were implanted subcutaneously 
into the backs of mice at a distance of approximately 9 mm from 
the inguinal LN. PLG vaccines resulted in a rapid enhancement 
in the numbers of phagocytic cells in the proximal inguinal LN, 
as four-fold increases in resident DCs and plasmacytoid DCs 
numbers were observed at day 3 (Fig. 4A). Vaccination induced 
persistent APC expansion in LNs, and at day 10, PLG vaccines 
maintained approximately three-fold increases in macrophage, 
DC and plasmacytoid DC numbers in LNs (in comparison to 
blank PLG matrices) (Fig. 4B). Consequently, significant T-cell 
expansion was observed at the draining inguinal LNs at day 10 
of vaccination, as a 2.5-fold increase in CD3(+) T-cell numbers 
(~1.3 x 106 T cells) was generated in comparison to blank matri-
ces (5 x 105 T cells) (Fig. 4C). Importantly, the T-cell expansion 
induced by PLG vaccines was mostly due to the expansion of the 
CD8(+) CTL subset, as their numbers in LNs increased similarly 
in scale, from 2.8 x 105 CTLs (blank matrices) to 8.2 x 105 CTLs 
(PLG vaccines) at day 10 of vaccination (Fig. 4C). Provision 
of persistent CpG-ODN signaling, alongside antigenic signals 
(tumor lysate), was required of the vaccines’ ability to induce 
polarization of LN T cells toward CD8(+) CTL expansion (Fig. 
4C) and to downregulate FoxP3(+) T regulatory cell activity in 
LNs (Fig. 4D and E). The ratio of CD8(+), cytotoxic T cells 
to Treg cells was approximately three-fold higher in animals 
treated with scaffold formulations that included danger signal-
ing in addition to GM-CSF and tumor lysate delivery (Fig. 4E). 
FoxP3 T cells may suppress the cytotoxicity of CD8(+) T cells 
and extinguish vaccine activity, and the results presented in this 
study confirm previous observations that persistent or unopposed 
GM-CSF signaling can cause the generation of Treg cells and 
immunosuppressive pathways, and TLR antagonism by danger 
signaling may override these effects and enhance anti-tumor 
responses.19,25-28
Discussion
Many infections provide antigenic and stimulatory signals to 
the immune system that activate DCs, which then process and 
present instructive signals to prime effector T-cell responses. ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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Figure 2. Kinetics of Dc and T-cell infiltration into pLG vaccine site. (A) hematoxylin and eosin staining of sectioned pLG vaccines explanted from 
subcutaneous pockets in the backs of c57BL/6J mice after 3 and 14 d. (B) FAcS histograms of cD11c(+) Dcs and cD3(+) T cells infiltrating pLG matrices 
loaded with approximately 3,000 ng GM-cSF, 100 μg cpG-ODN and tumor antigens at days 5 and 12. histograms of isotype control (tinted line) are 
also included. (c) The total number of cD11c(+) Dcs and cD3(+) T cells isolated from pLG vaccines as a function of time post implantation. (D) The 
ratio of cD8 Tcells vs. cD4 Tcells residing within pLG vaccines at day 12 post-implantation. Values in (c and D) represent mean and standard deviation 
(n = 4 or 5). **p < 0.01 as compared with controls.
The kinetics of these responses to infection have been described 
extensively, including the rapid recognition and activation of DC 
populations and the time lag associated with T-cell priming and 
expansion.5-10 Optimally, these effector T cells mediate the kill-
ing of infectious agents and persist until antigens and pathogens 
are cleared, but tumors have evolved mechanisms to evade and 
subdue these destructive responses.1-3,11,12 Based on these consid-
erations, it is intuitively appealing to hypothesize that vaccine-
based therapy for established tumors may require not only the 
stimulation of innate DC responses, but also the maintenance of 
adaptive T-cell responses. This implies that vaccine formulations 
must be able to present antigen in an immunostimulatory envi-
ronment for extended periods to maintain T-cell responses until 
all tumor cells have been killed by effectors.
In this study, we determined the long-term vaccine kinetics 
of both innate DC responses and effector T-cell responses to a 
biomaterial-based vaccine and its relationship to vaccine efficacy. 
Previously, the PLG vaccine system demonstrated significant 
and specific CD8(+) CTL induction, both locally at the vaccine 
site and systemically in spleens and via the eradication of B16 
melanoma tumors.18,19 The immune responses to PLG vaccines 
as outlined here, propagate with kinetics similar to viral and 
bacterial infections, as described by other researchers.6-10 These 
results also indicate that the vaccine’s ability to coordinate per-
sistent DC activation and T-cell responses in situ was manifested 
both locally and systemically, resulting in enhanced APC genera-
tion in LNs followed by T-cell expansion with similar kinetics 
(Figs. 2 and 4). A unique feature of these PLG vaccines is their ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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Figure 3. Kinetics of IL-12 and IFNγ production at vaccine site. (A) The concentrations of IL-12 at the implant site of pLG vaccines as a function of time 
post-implantation. (B) The in vivo concentration of IL-12 at the implant site of blank matrices (Blank), pLG vaccines (GM+cpG+LYS) or matrices loaded 
with either Lysate alone (Lys), Lysate with approximately 3,000 ng of GM-cSF (GM+Lys) or Lysate with approximately 100 μg peI-cpG-ODN (cpG+Lys) 
or the combination of GM-cSF and peI-cpG-ODN (GM+cpG) at day 12 after implantation into the backs of c57BL/6J mice. (c) The concentration of 
IFNγ at the implant site of pLG vaccines as a function of time post-implantation. (D) The in vivo concentration of IFNγ at the implant site of blank matri-
ces (Blank), pLG vaccines (GM+cpG+LYS) or matrices loaded with either Lysate alone (Lys), Lysate with 3,000 ng of GM-cSF (GM+Lys) or Lysate with 100 
μg peI-cpG-ODN (cpG+Lys) or the combination of GM-cSF and peI-cpG-ODN (GM+cpG) at day 12 after implantation into the backs of c57BL/6J mice. 
Values in (A–D) represent mean and standard deviation (n = 4 or 5). *p < 0.05 **p < 0.01 as compared with controls.
prolonged maintenance of local T-cell responses (detectable at 
28 d) by sustained antigen presentation after the conclusion of 
DC recruitment and activation, which likely underlies the thera-
peutic efficacy of the vaccine.
Vaccinations utilizing melanoma vaccines fabricated into PLG 
matrices resulted in two distinct phases of immune responses in 
situ. First, innate responses included macrophages/monocyte 
infiltration detected at 24 h (Fig. 2), and DC activation began 
at day 3, peaked at day 5 and subsided at day 12 post-vaccination 
(Fig. 2B and C). The second phase consisted of adaptive T-cell 
responses consisting mostly of CD8(+) cytotoxic T-lymphocytes 
(CTLs) (Fig. 2D), which began at day 5, peaked at day 12 and 
subsided at day 28 (Fig. 2A and B). Indeed, CTL responses to the 
PLG matrix manifested potent effector function, with vaccination 
resulting in a prototypical activation phase that gradually pla-
teaus and is followed by a contraction phase as the antigen is 
cleared. The time lag associated with the onset of the effector 
response (detected at day 5 after implantation) is likely the time 
required to induce sufficient DC recruitment and priming.
The vaccine also induced persistent IL-12 and IFNγ produc-
tion consistent with DC and T-cell infiltration into the vaccine 
site; this is a hallmark of Th1 and cytotoxic T-cell responses 
against tumors. Previously, it was shown that these PLG vaccines 
can induce CTLs expressing TCRs specific for the melanoma 
antigen Trp-2,18,19 and the kinetics of cytotoxic T-cell homing to 
the vaccine site is likely in response to prolonged antigen presen-
tation (tumor lysates) by the PLG matrix. The timing of the peak 
levels of T-cell infiltration and IFNγ production at the vaccine ©2 0 1 1   L a n d e s   B i o s c i e n c e .
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Figure 4. For figure legend, see page 73.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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site coincided with a significant drop in local DC numbers at 
days 7–12 that is likely due to CD8(+) T-cell cytotoxicity against 
these antigen-presenting cells,18,19 as these cells continue to pro-
cess and present the tumor antigens that killer T cells are being 
primed against. Importantly, similar kinetics of APC recruitment 
and CTL expansion were observed systemically in the draining 
inguinal LNs. These results indicate that vaccination with this 
system requires stimulation for at least 3 d to induce the onset 
of innate immunity (i.e., DC responses), and that effector CTL 
responses can be maintained until antigen is depleted from the 
vaccine site.
The relationship between vaccine duration and vaccine effi-
cacy suggests the importance of prolonged maintenance of effec-
tor responses against established tumors. By explanting the PLG 
vaccines between 1 and 7 d—before the onset of significant effec-
tor CTL responses in situ—little to no benefit was observed in 
regards to tumor progression or survival. When the scaffolds were 
implanted for greater than 7 d, the engineered matrices efficiently 
maintained potent T-cell responses by providing a secondary 
site of tumor antigen presentation after the primary induction 
of innate DC activation had occurred. Vaccination times that 
included the maintenance of T-cell responses greater than 7 d 
resulted in enhanced prophylactic protection and the significant 
regression of solid tumors. In tumor-bearing animals, prolonged 
durations of vaccination (>16 d) significantly augmented persis-
tent CTL responses locally and slowed tumor progression, result-
ing in an almost three-fold increase in mouse survival.
Current vaccination methods include protein fusions, anti-
body conjugation to antigen and viral gene therapy to enhance 
half-life, targeting and immunogenicity of antigen. Biomaterials 
have also been utilized to sustain or target antigen delivery to 
immune cells in animal models,13,14 predominantly as particulate 
systems. Although current biomaterials are capable of extending 
the in vivo half-life of antigen delivery from hours to days, allow-
ing for prolonged DC stimulation, this lifespan is shortened by 
biodegradation, lymphatic drainage and renal clearance.13,14,29-31 
Thus, the ability of current methods to effectively coordinate 
adaptive responses (for example, T cells) is likely inadequate, as 
exemplified by their inability to stimulate reproducible tumor 
regression against solid and invasive tumors in mice and man,11 
and this may be attributed to a rapid loss of vaccine activity (days 
to a week) in vivo.
In summary, this study highlights the benefit of augmenting 
immune cell responses in therapeutic vaccine formulations and 
suggests specific temporal requirements for the bioactivity of vac-
cine systems. Our data combined with past studies of immune 
responses to infection2-10 indicate that approximately 7 d of 
immunostimulation by vaccines is required to stimulate effec-
tor T-cell responses. Importantly, long-term antigen stimulation 
(> 12 d; after DC activation) provided a distinct benefit in the 
maintenance of CTL responses and the efficacy of therapeutic 
vaccines to established tumors. This duration of stimulation is 
predominantly absent in current vaccine approaches.
Materials and Methods
GM-CSF and CpG-ODN incorporation and bioactivity. To 
determine the incorporation of GM-CSF and CpG-ODN into 
PLG scaffolds, 125I-labeled hr-GM-CSF (Perkin Elmer) and P33-
CpG-ODN 1826 (oligofactory; radiolabeled at Perkin Elmer) 
were utilized as a tracer. The amount of 125I-hr-GM-CSF and 
P33-CpG-ODN in PLG vaccines was determined at each time 
point by counting the radioactivity in a gamma counter or a scin-
tillation counter.
Total protein content. To measure the total protein incorpo-
rated (tumor lysate) into the PLG vaccines, 1.0 N NaOH was 
utilized to dissolve the PLG scaffold and solubilize the protein 
incorporated into the device. Protein was quantified using the 
Micro BCA Protein Assay Kit. A set of five devices were used for 
these analyses.
Matrix fabrication. An 85:15, 120 kD copolymer of D,L-lactide 
and glycolide (PLG) (Lakeshore Biomaterials, Birmingham, 
Al) was utilized in a gas-foaming process to form porous PLG 
matrices.32 In brief, PLG microspheres encapsulating GM-CSF 
were first made using a standard double emulsion process.33 PLG 
microspheres were then mixed with 150 mg of the porogen sucrose 
(sieved to a particle size between 250 μm and 425 μm) and com-
pression molded. The resulting disc was allowed to equilibrate 
in a high-pressure CO2 environment, and a rapid reduction in 
pressure causeed the polymer particles to expand and fuse into 
an interconnected structure.20 The sucrose was leached from the 
scaffolds by immersion in water, yielding scaffolds that were 90% 
porous. To incorporate tumor lysates into PLG scaffolds, biop-
sies of B16-F10 tumors that had grown subcutaneously in the 
backs of C57BL/6J mice (Jackson Laboratory, Bar Harbor ME), 
were digested in collagenase (250 U/ml) (Worthington, 
Lakewood, NJ) and suspended at a concentration equivalent to 
107 cells per ml after filtration through 40 μm cell strainers. The 
tumor cell suspension was subjected to four cycles of rapid freeze 
in liquid nitrogen and thawed (37°C) and then centrifuged at 
400 rpm for 10 min. The supernatant (1 ml) containing tumor 
lysates was collected, incubated with the PLG microspheres and 
lyophilized, and the resulting mixture was used to make PLG 
scaffold-based cancer vaccines. To incorporate CpG-ODNs into 
Figure 4 (See opposite  page). effects of pLG vaccination on cells in draining lymph nodes. (A and B) The number of phagocytic cells, cD11b(+)
cD11c(-) macrophages, cD11c(+) Dcs and pDcA-1(+)cD11c(+) plasmacytoid Dcs, in the draining inguinal lymph nodes of mice at (A) day 3 and at (B) day 
10 after implantation of blank matrices (Blank) or pLG matrices containing GM-cSF and Lysate (GMcSF+LYS) only or pLG vaccines (GMcSF+Lys+cpG). 
(c) The number of T cells, cD3(+) T cells, cD3(+)cD8(+) T cells and cD3(+)cD4(+) T cells, in the draining inguinal lymph nodes of mice at day 10 after 
implantation of blank matrices (Blank) or pLG matrices containing GM-cSF and Lysate (GMcSF+LYS) only or with cpG-ODN (GMcSF+Lys+cpG). (D) The 
number of cD3(+)Foxp3(+) Tregs in the draining inguinal lymph nodes of mice at day 16 after implantation of blank matrices (Blank) or pLG matrices 
containing GM-cSF and Lysate (GMcSF+LYS) only or with cpG-ODN (GMcSF+Lys+cpG). (e) The ratio of cD8 T cells vs. cD3(+)Foxp3(+) Tregs in the 
draining inguinal lymph nodes of mice at day 16 after implantation of pLG matrices containing GM-cSF and Lysate (GMcSF+LYS) only or with cpG-
ODN (GMcSF+Lys+cpG). Values represent mean and standard deviation (n = 4 or 5). *p < 0.05 **p < 0.01 as compared with controls.©2 0 1 1   L a n d e s   B i o s c i e n c e .
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PLG scaffolds, CpG-ODN 1826, 5’-TCC ATG ACG TTC CTG 
ACG TT-3’ (Oligofactory, Holliston, MA) was first condensed 
with poly(ethylenimine) (PEI, Mn ~60,000, Sigma Aldrich) mol-
ecules by dropping ODN-1826 solutions into PEI solution while 
vortexing the mixture.20,23,34 The charge ratio between PEI and 
CpG-ODN (NH3+:PO4-) was kept constant at 7 during con-
densation. PEI-CpG-ODN condensate solutions were then vor-
texed with 60 μl of 50% (wt/vol) sucrose solution, lyophilized 
and mixed with dry sucrose to a final weight of 150 mg. The 
sucrose-containing PEI-CpG-ODN condensate was then mixed 
with blank, GM-CSF and/or tumor lysate loaded PLG micro-
spheres to make PLG cancer vaccines.
In situ identification of DC and T-cell infiltration. Blank PLG 
matrices and matrices containing 3,000 ng GM-CSF alone or 
in combination with either 1, 10, 50 or 100 μg CpG-ODN 
(studies were also performed with tumor lysates co-presented 
with either 3,000 ng GM-CSF or 100 μg CpG-ODN alone or 
in combination) were implanted into subcutaneous pockets on 
the back of 7–9 week old male C57BL/6J mice. For histological 
examination, scaffolds were excised and fixed in Z-fix solution, 
embedded in paraffin and stained with hematoxylin and eosin. 
For SEM analysis, matrices were sputter coated with gold prior 
to visualization.
To analyze DC and T-cell recruitment, scaffolds were 
excised at various time points, and the ingrown tissue was 
digested into single cell suspensions using a collagenase solu-
tion (Worthingtion, 250 U/ml) that was agitated at 37°C 
for 45 min. The cell suspensions were then poured through a 
40 μm cell strainer to isolate cells from scaffold particles, and 
the cells were pelleted and washed with cold PBS and counted 
using a Z2 coulter counter (Beckman Coulter). To assess DC 
infiltration, subsets of the total cell population isolated from 
PLG matrices were then stained with primary antibodies (BD 
PharMingen, San Diego, CA) conjugated to fluorescent markers 
to allow for analysis by flow cytometry. APC-conjugated CD11c   
(dendritic cell marker) stains were conducted for DC recruitment 
analysis. To assess T-cell infiltration, PE-Cy7 conjugated CD3 
stains were performed in conjunction with APC-conjugated 
CD8a (CD8 T cells), FITC-conjugated CD4 (CD4 T cells) 
and analyzed with flow cytometry. Cells were gated according 
to positive FITC, APC and PE using isotype controls, and the 
percentage of cells staining positive for each surface antigen was 
recorded.
Tumor growth assays and in situ cytokine concentrations. PLG-
based vaccines were developed utilizing matrices incorporating 
melanoma tumor lysates, 3,000 ng GM-CSF and 100 μg PEI-
CpG-ODN condensates and were implanted subcutaneously 
into the lower left flank of C57BL/6J mice. For prophylactic vac-
cinations, animals were challenged 14 d later with a subcutaneous 
injection of 105 B16-F10 melanoma cells (ATCC, Manassas, NJ) 
in the back of the neck. To assess the effect of the duration of 
vaccination, PLG vaccines were explanted at days, 1, 3, 7, 12 and 
16 d after implantation. Animals were monitored for the onset of 
tumor growth (approximately 1 mm3) and sacrificed for humane 
reasons when tumors grew to 20–25 mm (longest diameter).
To determine in vivo GM-CSF concentrations in adjacent tis-
sue and IL-12p70 and IFNγ concentrations at the matrix implant 
site, excised tissue was digested with tissue protein extraction 
reagent (Pierce). After centrifugation, the concentration of 
GM-CSF, IL-12p70 and IFNγ in the supernatant was then ana-
lyzed with ELISA (R&D systems), according to the manufactur-
ers instructions.
Statistical analysis. All values in the present study were 
expressed as mean ± SD. The significant differences between the 
groups were analyzed by a Student t-test and a p-value of less than 
0.05 was considered significant.
Note
Supplemental materials can be found at:
www.landesbioscience.com/journals/biomatter/article/16277
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